Literature DB >> 7779147

Studies on the in vitro and in vivo genotoxicity of [2,2-dimethyl-6- (4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.

A Heidemann1, S Tries, S Laufer, J Augustin.   

Abstract

[2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5- yl]-acetic acid (CAS 156897-06-2, ML 3000) was examined for genotoxic activity in bacteria and mammalian cells in vitro as well as in vivo. The substance did not increase gene mutation frequencies either in a bacterial system or in a cultured V79 cell line of the Chinese hamster. Both in vitro tests were conducted in the presence and absence of S9-mix. In the unscheduled DNA synthesis assay in vitro with primary rat hepatocytes, negative results were also obtained. A cytogenetic analysis of the bone marrow of male and female Wistar rats was performed. After oral application ML 3000 did not increase the number of cells with structural chromosomal aberrations. The results suggest that ML 3000 has no genotoxic potential in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779147

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration.

Authors:  Sheela Sharma; Jin Lee; Jianliang Zhou; Vernon E Steele
Journal:  Cancer Prev Res (Phila)       Date:  2011-05-11

Review 2.  Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone.

Authors:  Arrigo F G Cicero; Giuseppe Derosa; Antonio Gaddi
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Activity and potential role of licofelone in the management of osteoarthritis.

Authors:  Arrigo F G Cicero; Luca Laghi
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

4.  Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.

Authors:  Adam J Smolka; James R Goldenring; Sandeep Gupta; Charles E Hammond
Journal:  BMC Gastroenterol       Date:  2004-02-10       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.